Titan Biotech Reports Mixed Financial Results Amid Declining Profitability in March 2025

Titan Biotech, a microcap company in the specialty chemicals industry, has recently reported its financial results for the quarter ending March 2025. The results indicate a complex financial landscape for the company, with notable evaluation changes reflected in its score, which has shifted to -9 from -13 over the past three months. On a positive note, Titan Biotech has achieved its highest cash and cash equivalents in the last six half-yearly periods, reaching Rs 10.03 crore, suggesting an improvement in short-term liquidity. However, several key metrics reveal challenges for the company. Profit Before Tax (PBT) has shown a significant decline of 38.03% year-on-year, amounting to Rs 3.65 crore. Additionally, net sales have decreased to Rs 35.17 crore, marking a drop of 11.90% year-on-year and representing the lowest sales figure in the last five quarters. Profit After Tax (PAT) for the latest six months stands at Rs 8.44 crore, reflecting a year-on-year decline of 30.65%. Furthermore, operating profit and earnings per share have also reached their lowest levels in recent quarters, indicating a trend of declining profitability. For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.